NASDAQ · Biotechnology

Immunome, Inc. (IMNM) Stock

$19.51 +1.03% NASDAQ: IMNM Healthcare

Valuation

MetricValue
Price$19.51
Market Cap$1.86B
P/E Ratio-8.23
P/B Ratio4.51
P/S Ratio285.42
EPS (TTM)$-2.43
52-Week High$30.06
52-Week Low$12.41
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-50.56%
ROA-44.98%
ROCE-51.06%
Gross Margin-3057.14%
Operating Margin-3057.14%
Net Margin-3028.57%
Debt/Equity0.01
Current Ratio14.69

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$14.0M$9.0M$7.0M
Operating Profit$-25.0M$-37.0M$-110.0M$-306.0M$-214.0M
Net Profit$-25.0M$-37.0M$-107.0M$-293.0M$-212.0M
EPS$-2.14$-3.09$-5.38$-5.00$-2.43
Op Margin——-781.4%-3382.4%-3084.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$24.0M$149.0M$240.0M$683.0M
Total Liabilities$10.0M$7.0M$29.0M$59.0M$49.0M
Cash$49.0M$20.0M$99.0M$143.0M$653.0M
Borrowings$0$0$2.0M$5.0M$4.0M

Latest News

What This Immunome Sale Means a Day Before a Big FDA Milestone Motley Fool · Jul 12, 2026 Immunome Stock Up 32% in a Month: Here's What You Should Know Zacks · Jul 10, 2026 Immunome Says FDA Accepted NDA for Desmoid Tumors Drug MT Newswires · Jul 8, 2026 Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors Business Wire · Jul 8, 2026 Immunome Insider Sold Shares Worth $2,412,522, According to a Recent SEC Filing MT Newswires · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-18.0M$-29.0M$-8.0M$-111.0M$-191.0M
Investing Cash Flow$0$0$-31.0M$-139.0M$51.0M
Financing Cash Flow$1.0M$0$116.0M$-9.0M$0
Net Cash Flow$9.0M$-29.0M$78.0M$45.0M$510.0M
Free Cash Flow$-18.0M$-29.0M$-8.0M$-164.0M$-201.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.49
EV / EBITDA-7.10
FCF Yield-10.97%
Quick Ratio15.08
Interest Coverage0.00
Return 1Y106.68%
Return 3Y221.35%
Return 5Y34.43%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVBPArriVent BioPharma, Inc. $17.15 +2.63% -7.60 $798.76M 0.00%
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
CLDXCelldex Therapeutics, Inc. $29.64 +1.14% -7.26 $1.97B 0.00%
CRVSCorvus Pharmaceuticals, Inc. $10.13 -0.83% -17.03 $851.46M 0.00%
IMCRImmunocore Holdings plc $31.95 -3.42% -85.34 $1.62B 0.00%

About Immunome, Inc.

Immunome, Inc. (IMNM) stock trades at $19.51 with a market capitalization of $1.86B. The stock is valued at a price-to-earnings (P/E) ratio of -8.23, price-to-book of 4.51, price-to-sales of 285.42. Over the past 52 weeks the stock has ranged between $12.41 and $30.06, and currently trades 35.1% below its 52-week high.

On profitability, Immunome, Inc. generates a return on equity (ROE) of -50.56%, return on capital employed of -51.06%, an operating margin of -3057.14%, a net profit margin of -3028.57%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1176.71 +0.61% JNJ Johnson & Johnson $261.15 +1.82% ABBV AbbVie Inc. $277.39 +1.82% MRK Merck & Company, Inc. Common Stock (new) $146.33 +2.77% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.12 +1.93% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $659.71 +1.19% AMGN Amgen Inc. $415.61 +2.01% GILD Gilead Sciences, Inc. $151.29 +2.85% ABT Abbott Laboratories $99.16 +0.68% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides